SOTYKTU (Bristol-Myers Squibb Australia Pty Ltd)
Product name
SOTYKTU
Date registered
Evaluation commenced
Decision date
Approval time
227 (255 working days)
Active ingredients
deucravacitinib
Registration type
EOI
Indication
Psoriatic Arthritis
SOTYKTU is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response to, or who have been intolerant to, a prior disease modifying therapy (DMARD). SOTYKTU may be used as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs).